Stopping bisphosphonate therapy in people at risk of bone fractures must be carefully considered
The major rationale for starting anti‐resorptive drug treatment in people with osteoporosis is that the risk of further fractures is 2–4 times and that of mortality 2–3 times as great for someone with a fragility fracture as for other people of the same age. This applies to virtually all fractures, and particularly during the 5 years after a fragility fracture.1,2,3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Chen W, Simpson JM, March LM, et al. Comorbidities only account for a small proportion of excess mortality after fracture: a record linkage study of individual fracture types. J Bone Miner Res 2018; 33: 795–802.
- 2. Bliuc D, Nguyen ND, Alarkawi D, et al. Accelerated bone loss and increased post‐fracture mortality in elderly women and men. Osteoporos Int 2015; 26: 1331–1339.
- 3. Bliuc D, Alarkawi D, Nguyen TV, et al. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2015; 30: 637–646.
- 4. van Geel T, Bliuc D, Geusens PPM, et al. Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study. PLoS One 2018; 13: e0198006.
- 5. Bliuc D, Nguyen ND, Nguyen TV, et al. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res 2013; 28: 2317–2324.
- 6. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low‐trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513–521.
- 7. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878–882.
- 8. Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 2014; 174: 1126–1134.
- 9. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON‐Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243–254.
- 10. Black DM, Thompson DE. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract Suppl 1999; 101: 46–50.
- 11. Eastell R, Hannon RA, Wenderoth D, et al. Effect of stopping risedronate after long‐term treatment on bone turnover. J Clin Endocrinol Metab 2011; 96: 3367–3373.
- 12. Kharazmi M, Hallberg P, Schilcher J, et al. Mortality after atypical femoral fractures: a cohort study. J Bone Miner Res 2016; 31: 491–497.
- 13. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 2015; 86: 100–107.
- 14. Zanchetta MB, Boailchuk J, Massari F, et al. Significant bone loss after stopping long‐term denosumab treatment: a post FREEDOM study. Osteoporos Int 2018; 29: 41–47.
- 15. Horne AM, Mihov B, Reid IR. Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif Tissue Int 2018; 103: 55–61.
- 16. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96: 972–980.
- 17. Lamy O, Gonzalez‐Rodriguez E, Stoll D, et al. Severe rebound‐associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 2017; 102: 354–358.
- 18. Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 2018; https://doi.org/10.1056/nejmoa1808082 [EPub ahead of print].
- 19. Guirguis‐Blake JM, Michael YL, Perdue LA, et al. Interventions to prevent falls in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018; 319: 1705–1716.
- 20. Royal Australian College of General Practitioners; Osteoporosis Australia. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. 2nd edition. Melbourne: RACGP, 2017. https://sydney.edu.au/medicine/cdpc/documents/resources/RACGP%20osteoporosis-guidelines_2017.pdf (viewed Oct 2018).
- 21. Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 2017; 101: 371–374.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
John Eisman has received consulting and research support from Amgen, Eli Lilly, Merck Sharp and Dohme, and Novartis. Christopher White has received consulting and research support from Amgen. None of these companies had any role in the preparation of this Editorial.